Improvement of industry-applied rifamycin B-producing strain, Amycolatopsis mediterranei, by rational screening.
An industrially applied rifamycin B-producing strain, Amycolatopsis mediterranei XC 1-02, was used for further screening. A special mutation and screening procedure was adopted to select a strain, which can alleviate the inhibition caused by both aromatic amino acid and p-hydroxybenzoic acid in the pathway of rifamycin B biosynthesis as well as enhance the production of propionate, one of the precursors of rifamycin B biosynthesis. By the above methods, a strain A. mediterranei XC 9-25 was obtained, and its rifamycin B productivity in shaking flask reaches 10 g/L, which is 2.38 times higher than that of the ancestral strain XC 1-02. The productivity of rifamycin B fed-batch fermentation in 60000 L fermentor with A. mediterranei XC 9-25 reached 19.11 g/L.
Jin
Zhi Hua
ZH
Institute of Bioengineering, College of Materials Science and Chemical Engineering, Zhejiang University, Hangzhou 310027, P. R. China.
Lin
Jiang Ping
JP
Xu
Zhi Nan
ZN
Cen
Pei Lin
PL
D000192:Actinomycetales / Q000187:drug effects / Q000235:genetics* / Q000254:growth & development* / Q000378:metabolism; D024322:Amino Acids, Aromatic / Q000494:pharmacology; D001709:Biotechnology / Q000379:methods*; D003470:Culture Media; D005285:Fermentation; D009154:Mutation; D010226:Parabens / Q000494:pharmacology; D011422:Propionates / Q000378:metabolism; D012294:Rifamycins / Q000096:biosynthesis*; D014364:Tryptophan / Q000494:pharmacology; D014466:Ultraviolet Rays
D024322:Amino Acids, Aromatic; D003470:Culture Media; D010226:Parabens; D011422:Propionates; D012294:Rifamycins; C033974:rifamycin B; D014364:Tryptophan; C038193:4-hydroxybenzoic acid